Engflag

Doxazosin

Quick links to important sections

Doxazosin

Selected form

Doxazosin_DE

Method of action: Alpha-Adrenergic Blocking, Alpha-Adrenolytic, Antihypertensive, Antispasmodic, Corrective Disorder Of Urination Or Dysuria, Hypotensive, Lipid-Lowering, Vasodilator

Treatment option: Hypertension, Benign Prostatic Hyperplasia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doxazosin

Property Description
Active ingredient Doxazosin mesylate
Form Oral tablet (immediate and extended-release)
Pharmacological class Alpha-1 adrenergic receptor antagonist (α1-blocker)
General purpose Manages pressure and eases muscle resistance
Origin Synthetic quinazoline derivative

What Type of Medication is Doxazosin?

Doxazosin is a synthetic, prescription-only medication (Rx) that belongs to the pharmacological class known as alpha-1 adrenergic receptor antagonists, or α1-blockers. This medication is chemically identified as a quinazoline derivative and contains a single active ingredient, doxazosin mesylate, making it a monotherapy product. Its primary mechanism involves blocking signals that cause certain muscle contractions, a function contributing to its systemic effects. Specifically, the medication blocks the effect of natural body chemicals on the muscles in the walls of blood vessels, helping them relax. This role establishes Doxazosin as an antihypertensive agent and a urological agent.

Doxazosin Forms and General Application

Doxazosin is available as an oral dosage form, presented as both immediate-release tablets and extended-release tablets (sustained-release versions). The distinction in form ensures patients can use an immediate-release formulation for rapid effect or an extended-release tablet for consistent, long-term action throughout the day. This is a differentiating factor within its class, as not all α1-blockers offer this extended-release option. This oral administration and the core mechanism provide the drug's general benefit: selective antagonism leads to the relaxation of smooth muscle in specific areas, including the walls of blood vessels and the tissues around the bladder and prostate. This fundamental effect helps manage pressure by facilitating peripheral vasodilation and easing localized resistance within the urinary tract.

Regulatory References

  1. (NIH DailyMed Label)

What side effects are possible with Doxazosin?

Possible Side Effects and Safety Information

Doxazosin's safety profile, as documented in official prescribing information, is defined by adverse reactions classified by frequency and affected physiological systems. The most commonly reported effects are related to its action as an alpha-1 blocker, primarily involving the vascular and nervous systems.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their reported incidence:

Classification Examples of Reactions Affected Systems (SOC)
Very Common Dizziness, Fatigue/Malaise Nervous, General
Common Postural Hypotension, Headache, Somnolence, Edema, Nausea, Rhinitis, Palpitations Vascular, Nervous, General, Gastrointestinal, Respiratory
Uncommon Syncope, Myocardial Infarction, Cerebrovascular accident Nervous, Cardiac
Very Rare Priapism, Jaundice, Hepatitis, Cholestasis Reproductive, Hepatobiliary

Time- and Population-Specific Safety Notes

The risk of postural hypotension and syncope (fainting) is officially documented as being highest in the first few hours following the initial dose or after a dose increase. This exposure-related pattern warrants specific attention.

Serious Adverse Reactions officially noted include Syncope, Priapism, and rare occurrences of Hepatitis/Cholestasis.

Population-Specific Restrictions exist, particularly regarding older adults, who may have an increased risk of orthostatic hypotension. Use of doxazosin is not recommended in patients with severe hepatic impairment due to limited clinical experience. Additionally, the drug is associated with the risk of Intraoperative Floppy Iris Syndrome (IFIS) in patients undergoing cataract surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Doxazosin as an exaggeration of its primary effects, primarily targeting the cardiovascular system.

Documented Overdose Manifestation

The most likely and critical manifestation of acute overdosage is hypotension (a marked drop in blood pressure).

When to Seek Immediate Medical Help

Immediate emergency medical attention must be sought if an overdose is suspected or has occurred. Contact a poison control center or emergency services immediately. The critical nature of the overdose is based on the risk of severe, uncontrolled blood pressure reduction.

Emergency Actions and Management

Management of a Doxazosin overdose is symptomatic and supportive, according to official labeling. Key regulatory instructions for overdose response include:

Action Area Regulatory Requirement
Patient Position The patient should be kept in a supine position (lying down).
Immediate Support Administer supportive treatment to correct hypotension.
Fluid Management If the supine position is insufficient, consider treatment for shock, typically involving volume expanders.
Further Intervention If necessary, a vasopressor may be required.

In all cases, measures should be taken to remove any unabsorbed drug from the gastrointestinal tract. Treatment must align with standard medical protocols for acute drug overdosage.

Therapeutic Uses of Doxazosin

Doxazosin is a medication applied across domains where additional symptomatic support is needed, primarily addressing conditions characterized by periods of heightened symptoms. The core therapeutic areas are the management of high blood pressure (hypertension) and the symptomatic treatment of benign prostatic hyperplasia (BPH).

In clinical application, Doxazosin is commonly used to help with BPH, a condition where symptoms related to physical discomfort interfere with daily functioning. The two main indications include: managing high blood pressure and easing the urinary symptoms associated with BPH. Specifically, the medication assists with maintaining functional stability, helping to ease symptoms related to inflammatory or irritative states, which may become intense or disruptive. Patients often describe the benefit as feeling more at ease during daily routines:

“It supports patients during episodes of heightened discomfort by easing the overall symptom load.”

For hypertension, Doxazosin supports general well-being during symptomatic phases by addressing symptoms related to heightened physiological activity, which in turn contributes to easing the overall systemic burden. It is relevant when supportive symptom management is appropriate.

Quick Fact: Support for easing urinary difficulties and physical discomfort during symptomatic BPH phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This information details Doxazosin eligibility and non-eligibility strictly based on official regulatory documentation.

Classification Eligibility Status/Condition
Absolute Contraindications Hypersensitivity to doxazosin, other quinazoline derivatives, or excipients.
A history of orthostatic hypotension (a form of low blood pressure upon standing).
For BPH treatment: concomitant overflow bladder, anuria, or progressive renal insufficiency (as monotherapy).
Conditional Contraindications BPH patients with chronic urinary tract infection, bladder stones, or upper urinary tract congestion.
Population Exclusions Pediatric patients (under 18 years): Safety and efficacy are not established.
Patients with severe hepatic impairment: Use is not recommended due to lack of clinical experience.
Use in Special Populations Pregnancy: Lack of controlled human data; use is only permitted if the potential benefit outweighs the potential risk.
Lactation: Use is generally not recommended or considered contraindicated due to risk of excretion into human milk.
Caution Required Patients with mild to moderate hepatic impairment: Must be administered with caution and careful dose titration.
Patients scheduled for cataract surgery: Current or past use must be disclosed to the surgeon.
Patients starting treatment for BPH: Must be screened for prostate cancer beforehand.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for doxazosin outlines interactions primarily classified by their pharmacokinetic and pharmacodynamic outcomes. No medicinal product is strictly classified as a contraindication based solely on drug-drug interaction risk.

Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Substance Categories Official Outcome / Restriction
Additive Hypotension PDE-5 Inhibitors (e.g., sildenafil), Other Antihypertensives (e.g., beta-blockers, calcium antagonists) Potential for additive blood pressure lowering effects and symptomatic hypotension.
Reduced Efficacy Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the antihypertensive effect of doxazosin.
Exposure Increase Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin) Doxazosin is a CYP3A4 substrate. Co-administration requires caution due to potential for increased systemic exposure.

Administration and Condition-Specific Constraints

Administration requires specific constraints documented in regulatory labeling. To mitigate the risk of symptomatic hypotension, a 6-hour time interval is recommended between the intake of immediate-release doxazosin and a PDE-5 inhibitor. Concomitant use with alcohol may also increase the risk for hypotension. Due to the drug’s complete hepatic metabolism, use in patients with severe hepatic impairment is not recommended, and caution is advised for all patients with impaired hepatic function. Additionally, markedly increased gastrointestinal retention times can specifically increase systemic exposure to the extended-release formulation.

Mechanism of Action

Primary Blockade of Alpha-1 Adrenoceptors

The primary mechanism of Doxazosin involves the selective and competitive antagonism of post-junctional mathbfalpha1-adrenoceptors, which are the main biological targets located on smooth muscle cells. This action interrupts the signal from the sympathetic neurotransmitter norepinephrine, thereby inhibiting the chemical command for muscle contraction and initiating a mechanistic cascade resulting in smooth muscle relaxation.

Dual Modulation of Vascular and Urogenital Tone

This mechanism produces a dual-system physiological effect by targeting alpha1-subtypes in two distinct areas: the vascular walls (alpha1B/alpha1D) and the lower urinary tract (alpha1A). This targeted inhibition results in simultaneous vasodilation in the circulatory system and smooth muscle relaxation in the prostate and bladder neck, causing a measurable change in both systemic peripheral vascular resistance and localized urethral resistance.

Dosage and Administration Information

How to Use Doxazosin — Administration Guidelines

This section details the instructions for using doxazosin. These guidelines define the standard administration, dose progression, and required procedural steps.

Administration Scope

Attribute Instruction
Route of Administration Oral
Frequency Once daily
Dosing Schedule Therapy must be started with a low initial dose and slowly increased (titrated) to the dose that produces the desired response.
Immediate-Release (IR) Tablet Start at 1 mg once daily. Dose increases (titration) occur typically at 1- to 2-week intervals up to a maximum dose of 8 mg once daily.
Extended-Release (ER) Tablet Start at 4 mg once daily. Dose increases (titration) occur after 3 to 4 weeks to 8 mg once daily, if necessary.
Timing in Relation to Meals IR Tablets can be taken with or without food, in the morning or evening. ER Tablets must be taken with breakfast.
Administration Method Swallow the tablet whole with liquid. Do not chew, divide, crush, or cut the tablets.
Missed Dose Rule If treatment is interrupted for several days, it must be re-initiated at the lowest starting dose (1 mg for IR or 4 mg for ER) and the titration process must be repeated.

Connection to the Overall Use Protocol

These instructions establish the precise daily schedule (once daily) and method of administration (oral, swallowed whole) required to ensure the drug is delivered and absorbed as intended. The mandated initial low dose and slow, incremental dose increases (titration) are the core procedural structure for finding the correct individual dosage. Compliance with the rule to restart at the lowest dose after any interruption of several days is necessary to maintain the established treatment protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Doxazosin

Evidence for Symptomatic Benign Prostatic Hyperplasia (BPH)

Research exploring Doxazosin’s role in BPH, a condition characterized by periods of heightened symptoms, largely rests on Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adult men with LUTS. Research examined whether the medication was associated with changes in validated symptom scores (like the IPSS) and functional urological outcomes such as maximum urinary flow rate ( Q max) and residual volume of urine left after voiding. Findings describe patterns related to outcomes reflecting daily functioning or activity level that were measured in the observed populations. Research highlights changes measured during the study period for both obstructive and irritative symptoms. Research monitored not only short-term symptom changes but also long-term functional outcomes related to disease progression.

Evidence for High Blood Pressure (Hypertension)

Doxazosin was studied for high blood pressure through a variety of studies, including placebo-controlled trials and large-scale, long-term Comparative Outcome Trials. These trials focused on outcomes monitoring physiological strain or stress and outcomes related to systemic imbalance, specifically measuring changes in blood pressure (both systolic and diastolic) at the end of the dosing period. Studies examined whether the use of Doxazosin was associated with long-term changes in the rates of specific composite cardiovascular events. Data show patterns related to blood pressure changes in the observed groups when Doxazosin was used alone or in combination with other drug classes.

What is Still Uncertain About the Research

Several areas of research surrounding Doxazosin still contain elements of uncertainty. For hypertension, the research includes limitations regarding its role as a first-line agent, as the Doxazosin monotherapy arm in the ALLHAT trial was prematurely discontinued. This event means that certainty remains low regarding long-term outcomes in that specific treatment context, and comparative evidence is lacking for certain outcomes. Follow-up durations were limited in some early trials, and data for certain specific groups remain insufficient.

How should Doxazosin be stored and disposed of?

How to Store and Dispose of Doxazosin

The official storage and disposal guidelines for Doxazosin oral tablets are established by regulatory bodies to maintain product quality and safety.

Storage Requirements

Doxazosin must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). It is mandatory to keep the medication in its original container, tightly closed, and protected from excess moisture, heat, and direct light. The product must be kept from freezing and stored safely out of the sight and reach of children.

Disposal Instructions

Patients must discard any unused medication after the expiration date. Do not throw unneeded or expired tablets into household trash or wastewater. Disposal should follow local pharmaceutical take-back programs or community guidelines to ensure proper handling and to avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

flagTaiwan

Equivalent of Doxazosin found in:

A-Z Index: